Trial paper is retracted as FDA keeps scrutiny on controversial vasculitis drug

BMJ 2026 Open access

Read full text
Authors: Chris Baraniuk
DOI: 10.1136/bmj-2026-100221
Cited by: 2
References: 2

Abstract

Trial paper is retracted as FDA keeps scrutiny on controversial vasculitis drug Chris BaraniukA crucial study that enabled the vasculitis drug avacopan, branded as Tavneos, to gain regulatory approval has been retracted by the New England Journal of Medicine (NEJM).

Fields of Study & Subjects

Vasculitis and related conditions Phosphodiesterase function and regulation Otitis Media and Relapsing Polychondritis

Publication details

Journal / source
BMJ
Publisher
BMJ
Volume
394
Pages
e100221–e100221
Publication date
8 July 2026
Language
EN